Literature DB >> 1559589

Erythromycin inhibits Cl secretion across canine tracheal epithelial cells.

J Tamaoki1, K Isono, N Sakai, T Kanemura, K Konno.   

Abstract

We studied the effect of the macrolide antibiotic erythromycin on bioelectrical properties of canine cultured tracheal epithelium under short-circuit conditions in vitro. Addition of erythromycin to the submucosal but not to the mucosal side dose-dependently decreased short-circuit current (Isc), the maximal decrease from the baseline value and the concentration required to produce a half-maximal effect (IC50) being 5.6 +/- 1.0 microA.cm-2 (mean +/- SE, p less than 0.001) and 18 microM, respectively. In contrast, other antibiotics including ampicillin, cephazolin and tetracycline were without effect. The erythromycin-induced decrease in Isc was not altered by amiloride, but it was abolished by bumetanide, diphenylamine-2-carboxylate2, and substitution of Cl in the bathing medium with gluconate (p less than 0.001, in each case). The effect of erythromycin on epithelial Isc was attenuated by pretreatment of cells with indomethacin but not with AA-861 a lipoxygenase inhibitor. Incubation of cells with erythromycin inhibited the release of prostaglandins E2 and F2 alpha from tracheal epithelial cells. These results indicate that erythromycin may selectively inhibit Cl secretion across airway epithelium through the inhibition of prostaglandin synthesis and suggest that this action possibly reflects its clinical efficacy in the treatment of airway hypersecretion.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1559589

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  20 in total

Review 1.  Macrolides in the respiratory tract in cystic fibrosis.

Authors:  Adam Jaffé; Mark Rosenthal
Journal:  J R Soc Med       Date:  2002       Impact factor: 5.344

Review 2.  Erythromycin and diffuse panbronchiolitis.

Authors:  H Koyama; D M Geddes
Journal:  Thorax       Date:  1997-10       Impact factor: 9.139

3.  Effects of roxithromycin and erythromycin on interleukin 8-induced neutrophil recruitment and goblet cell secretion in guinea pig tracheas.

Authors:  J Tamaoki; J Nakata; E Tagaya; K Konno
Journal:  Antimicrob Agents Chemother       Date:  1996-07       Impact factor: 5.191

4.  Antibiotic penetration into lung tissues.

Authors:  D Honeybourne
Journal:  Thorax       Date:  1994-02       Impact factor: 9.139

5.  Macrolide antibiotics protect against endotoxin-induced vascular leakage and neutrophil accumulation in rat trachea.

Authors:  J Tamaoki; N Sakai; E Tagaya; K Konno
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

Review 6.  Mechanisms of action and clinical application of macrolides as immunomodulatory medications.

Authors:  Soichiro Kanoh; Bruce K Rubin
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

7.  Lipopolysaccharide enhances bradykinin-induced signal transduction via activation of Ras/Raf/MEK/MAPK in canine tracheal smooth muscle cells.

Authors:  S F Luo; C C Wang; C T Chiu; C S Chien; L D Hsiao; C H Lin; C M Yang
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

Review 8.  Immunomodulatory effects of macrolide antibiotics in respiratory disease: therapeutic implications for asthma and cystic fibrosis.

Authors:  Sanjiv Sharma; Adam Jaffe; Garth Dixon
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

9.  Fourteen-member macrolides promote the phosphatidylserine receptor-dependent phagocytosis of apoptotic neutrophils by alveolar macrophages.

Authors:  Takeshi Yamaryo; Kazunori Oishi; Hiroyuki Yoshimine; Yoshiko Tsuchihashi; Kouji Matsushima; Tsuyoshi Nagatake
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

10.  Long term effect of erythromycin therapy in patients with chronic Pseudomonas aeruginosa infection.

Authors:  T Fujii; J Kadota; K Kawakami; K Iida; R Shirai; M Kaseda; S Kawamoto; S Kohno
Journal:  Thorax       Date:  1995-12       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.